Company Description
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally.
It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand.
It sells its products through traditional and digital beauty retailers and distributors, as well as online.
The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007.
NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
| Country | United States |
| IPO Date | Oct 26, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Justin M. Hall Esq. |
Contact Details
Address: 2000 Powell Street, Suite 1150 Emeryville, California 94608 United States | |
| Phone | (510) 899-8800 |
| Website | novabay.com |
Stock Details
| Ticker Symbol | NBY |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001389545 |
| CUSIP Number | 66987P201 |
| ISIN Number | US66987P3001 |
| Employer ID | 68-0454536 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Justin M. Hall Esq. | President, Chief Executive Officer, General Counsel, Chief Compliance Officer, Corporate Secretary and Director |
| Tommy Law | Controller, Interim Chief Financial Officer and Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | 8-K | Current Report |
| Apr 18, 2024 | ARS | Filing |
| Apr 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 18, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 8, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 5, 2024 | D | Notice of Exempt Offering of Securities |
| Mar 29, 2024 | 10-K/A | [Amend] Annual report |
| Mar 26, 2024 | 10-K | Annual Report |
| Mar 26, 2024 | 8-K | Current Report |
| Mar 25, 2024 | 8-K | Current Report |